Topics

Daiichi Sankyo's Hypertension Drug Hits Mark in Diabetic Nephropathy Trial

19:00 EST 7 Nov 2019 | BioSpace

The trial demonstrated that patients receiving esaxerenone has a significantly higher Urine Albumin-to-Creatinine Ratio (UACR) of 22.1% compared to 4.0% on placebo.

Original Article: Daiichi Sankyo's Hypertension Drug Hits Mark in Diabetic Nephropathy Trial

NEXT ARTICLE

More From BioPortfolio on "Daiichi Sankyo's Hypertension Drug Hits Mark in Diabetic Nephropathy Trial"

Quick Search

Relevant Topic

Urology
Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Urology Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Urology is a su...